Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05254015
Other study ID # 1R01MH127056-01A1
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date November 21, 2022
Est. completion date February 28, 2027

Study information

Verified date April 2023
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hoarding disorder (HD) is a chronic, progressive, and debilitating psychiatric condition that leads to devastating personal and public consequences, particularly for older adults. This confirmatory efficacy trial will advance our knowledge of the mechanisms of action in the treatment of HD as well as reduce symptom severity, disability, and community consequences.


Description:

Hoarding disorder (HD) is a chronic, progressive, and debilitating psychiatric condition that leads to devastating personal and community consequences, particularly for older adults. HD is defined by persistent difficulty discarding or parting with possessions due to distress associated with discarding, urges to save, and/or difficulty making decisions about what to keep and what to discard. As a result, clutter accumulates and fills active living areas, preventing the normal use of space and resulting in distress and disability. Community epidemiological reports estimate the prevalence of clinically significant hoarding symptoms at 7% in individuals over age 60 and even higher rates in those over age 70. HD is the only neuropsychiatric condition that progresses in severity and population prevalence with age apart from dementia. Inhibition and cognitive switching have been identified as key deficits in older adults with HD. These executive functioning areas are consistent with the RDoC cognitive control domain and particularly the goal selection, updating, representation, and maintenance subconstruct. Findings suggest that these deficits may contribute to the symptomatic expression of HD, degree of functional impairment, and modest responses to HD treatment. Furthermore, anticipatory and experiential fear and anxiety, consistent with the RDoC constructs of acute and potential threat, lead to sustained problems with discarding items and clutter accumulation. When these constructs are targeted, our group has produced clinically and statistically significant outcomes. Consistent with NIMH strategic goal 3.1, to arrive at effective treatment approaches for unmet therapeutic domains in behavioral science, this project seeks to conduct the first confirmatory efficacy trial for older adults with HD. We propose a RCT comparing CREST to a case management control condition for 150 adults age 50 and older with HD. We are examining age as a moderator and will therefore include both midlife and late life participants. An evaluation of treatment outcome, including hoarding severity and functional outcomes, will be conducted at baseline (0 months), mid-treatment (3 months), end of treatment (6 months), 3-month (9 months) and 6-month follow-up (12 months). Participants will receive 26 weekly 60-minute individual sessions over the course of 32 weeks maximum (6-7.5 months). They will receive 50% in home and 50% office visits. We will examine factors that mediate improvement in CREST (improved inhibition/cognitive switching and reduction in fear/anxiety of discarding items) through physiological, behavioral, self-report, and paradigm assessments. Individual factors (e.g., age and other demographic factors, baseline cognitive control, baseline hoarding severity) and treatment factors (e.g., session attendance) will be evaluated as moderators. The specific aims include determining confirmatory efficacy of CREST, mechanisms of CREST effects, and moderators of CREST. If successful, this project would lead to an effectiveness trial in a real world setting.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 150
Est. completion date February 28, 2027
Est. primary completion date February 28, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - adults age 50 and older - voluntary informed consent for participation - DSM-5 diagnosis of HD - HD as a primary, most severe diagnosis - stable on medications for at least 8 weeks Exclusion Criteria: - current psychosis or mania as measured by the Mini-International - current or history of any neurodegenerative disease - substance use disorder - current use of benzodiazepine medication - suicidality - current participation in exposure-based therapy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
Case Management
Case management includes linking to resources, monitoring health, and safety hazards.

Locations

Country Name City State
United States Guava Hall San Diego California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other DKEFS Cognitive Control (inhibition and cognitive switching) will be assessed using the Delis-Kaplan Executive Function System (D-KEFS), which was specifically designed to detect deficits in high-level cognitive functions and has demonstrated strong reliability and validity in various clinical populations. We will administer five tests from the D-KEFS that examine components of executive functioning, including inhibition (the Color-Word Interference Test), cognitive switching (Verbal Fluency, Trails, Design Fluency), and Planning (Tower). through study completion, an average of 1 year
Other Behavior Rating Inventory of Executive Function- Adult Version (BRIEF-A) The Behavior Rating Inventory of Executive Function- Adult Version (BRIEF-A) is a validated measure that captures views of an adult's executive functions or self-regulation their everyday environment. This will be used to assess nine non-overlapping theoretically and empirically derived clinical scales: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and Organization. through study completion, an average of 1 year
Other Behavioral Avoidance Task (BAT) Threat: Fear/Anxiety will be assessed via a Behavioral Avoidance Task (BAT), utilized for assessing avoidance to sorting and discarding possessions. The BAT has been validated for measuring avoidance in OCD samples, and will be adjusted for use in HD samples. through study completion, an average of 1 year
Other Heart Rate (HR) Threat response to discarding in beats per minute during BAT. through study completion, an average of 1 year
Other Skin Conductance Response (SCR) Threat response to discarding in changes in temperature. through study completion, an average of 1 year
Primary Change in Saving Inventory-Revised (SI-R) Hoarding symptom severity will be measured using the Saving Inventory-Revised (SI-R), a 23-item self-report measure used to assess common HD symptoms. Subscales include excessive clutter, compulsive acquisition, and difficulty discarding. The SI-R has demonstrated good internal consistency, concurrent validity, divergent validity, and test-retest reliability in clinical samples with HD. The total score will be used for analyses. through study completion, an average of 1 year
Primary Change in Self-report Clutter Image Rating (CIR) The Clutter Image Rating Scale (CIR) is a measure using a series of 9 photographs each of a kitchen, living room, and bedroom with varying levels of clutter. Participants and the rater independently select the photograph that most closely resembles each of the three rooms in the home. Internal consistency, test-retest reliability, inter-rater reliability, and correlations with validated HD measures for the CIR were high. through study completion, an average of 1 year
Secondary PROMIS-43 Profile v2. Functioning will be assessed with the PROMIS-43 Profile v2., which consists of a fixed collection of 6-item sets to assess global health and functioning (in physical, mental, and social domains). The PROMIS-43 assesses anxiety, depression, fatigue, pain interference, pain intensity, physical functioning, sleep disturbance, and ability to participate in social roles and activities. Substantial evidence supports the validity, reliability, and responsiveness to change of the PROMIS measures among adults with and without medical and mental health conditions. through study completion, an average of 1 year
Secondary UCSD Performance-Based Skills Assessment (UPSA-2) The UCSD Performance-Based Skills Assessment (UPSA-2) is an assessment of everyday functioning skills involved in household management (e.g., writing a shopping list based on a provided recipe), communication (e.g., rescheduling a doctor's appointment), finance (e.g., paying a utility bill), comprehension/planning (e.g., planning an outing), medication management (taking medications as planned), and transportation (e.g., reading comprehension of a bus schedule). The UPSA-2 has demonstrated high inter-rater reliability (0.91) and convergent validity with other performance-based measures. The total UPSA-2 summary score will be used for analyses. through study completion, an average of 1 year
Secondary UCSD SORT Test (U-SORT) The UCSD SORT Test (U-SORT) will be used to measure participants' organizational skills as they relate to functional capacity. During the administration of the U-SORT, participants are instructed to sort 42 household objects (e.g., bent and unbent paper clips, used and unused condiment packets) from a hypothetical "junk drawer" into either "keep" or "trash" piles. Participants are given two minutes to complete the task and one point is awarded for each correctly sorted item, for a total of 42 points. The U-SORT has high internal consistency (alpha = .86) and adequate convergent validity. The total U-SORT score will be used in analyses. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04934007 - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder N/A
Recruiting NCT04071990 - Family Involvement in CBGT of OCD: a Randomized Controlled Trial N/A
Completed NCT02541968 - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Recruiting NCT05391503 - Light Therapy for Obsessive-compulsive Disorder (OCD) N/A
Recruiting NCT04539951 - Pragmatic Trial of Obsessive-compulsive Disorder Phase 2
Completed NCT03416504 - Methods for Managing Intrusive Thoughts N/A
Not yet recruiting NCT06029738 - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD N/A
Recruiting NCT02844049 - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS N/A
Terminated NCT02909660 - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder N/A
Completed NCT02911324 - Cannabinoid Medication for Adults With OCD Phase 1/Phase 2
Completed NCT02217995 - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients N/A
Terminated NCT02234011 - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder Phase 2
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02655926 - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder N/A
Terminated NCT00758966 - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Phase 2
Completed NCT04919785 - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder N/A
Completed NCT00742664 - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Phase 1/Phase 2
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00074815 - Treatment of Obsessive Compulsive Disorder in Children Phase 3